Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.62 |
| ▸ | PTPRC | P08575 | 8/20 | 0.58 |
| ▸ | PTPRF | P10586 | 2/20 | 0.57 |
| ▸ | CDC25B | P30305 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8600693 | 0.80 | PTPN1 (0.75) | PTPN1NSD2HKDC1PTPRCPTPRF | |
| SCHEMBL197980 | 0.74 | PTPN1 (0.59) | PTPN1NSD2OPRM1OPRD1HKDC1 | |
| SCHEMBL6231543 | 0.73 | PTPRC (1.00) | PTPN1NSD2HKDC1PTPRCPTPRF | |
| SCHEMBL8992461 | 0.73 | PTPN1 (1.00) | PTPN1NSD2OPRM1OPRD1HKDC1 | |
| SCHEMBL8597428 | 0.73 | PTPN1 (0.65) | PTPN1NSD2OPRM1OPRD1HKDC1 | |
| SCHEMBL10719569 | 0.72 | PTPN1 (0.56) | PTPN1KDM4EALPLGAAALDH1A1 | |
| SCHEMBL8596446 | 0.72 | PTPN1 (0.64) | PTPN1NSD2HKDC1PTPRCPTPRF | |
| SCHEMBL6236312 | 0.72 | PTPN1 (1.00) | PTPN1NSD2HKDC1PTPRCPTPRF | |
| SCHEMBL29808966 | 0.72 | PTPN1 (1.00) | PTPN1NSD2HKDC1PTPRCPTPRF | |
| SCHEMBL11544154 | 0.72 | PTPN1 (0.56) | PTPN1NSD2OPRM1OPRD1HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939896-B2 | Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| EP-1259231-B1 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| US-20030119897-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119897-A1 | Cd45 inhibitors | PTPRC, CD2, HLA-C | PTPN1 18/4885NSD2 3281/4885OPRM1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.